Alternate-day tadalafil in the management of honeymoon impotence

Journal of Sexual Medicine

Volumn 5, Issue 6, 2008, Pages 1451-1454

  Ghanem, Hussein ^a   El dakhly, Mohamed ^a   Shamloul, Rany ^a,b  

^a CAIRO UNIVERSITY   (Egypt)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Erectile Dysfunction; Honeymoon Impotence; Tadalafil

Indexed keywords

PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; TADALAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; FLUSHING; HONEYMOON IMPOTENCE; HUMAN; IMPOTENCE; MALE; PENIS ERECTION; PRIORITY JOURNAL; PSYCHOTHERAPY; SEXUAL INTERCOURSE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 44949256283     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00748.x     Document Type: Article

References (18)

1. Badran W, Moamen N, Fahmy I, El-Karaksy A, Abdel-Nasser TM, Ghanem H. Etiological factors of unconsummated marriage. Int J Impot Res 2006; 18: 458-63.
2. Ghanem H, Zaazaa A, Kamel I, Anis T, Salem A, El Guindi A. Short-term use of sildenafil in the treatment of unconsummated marriages. Int J Impot Res 2006; 18: 52-4.
3. El-Meliegy A. A retrospective study of 418 patients with honeymoon impotence in an andrology clinic in Jeddah, Saudi Arabia. Eur J Sexol 2004; 13: 1-4.
4. Shamloul R. Management of honeymoon impotence. J Sex Med 2006; 3: 361-6.
5. Crowe M, Jones M. Sex therapy: The successes, the failure, the future. Br J Hosp Med 1992; 48: 474-9.
6. Masters WH, Johnson VE. Human sexuality inadequacy. Boston, MA: Little Brown; 1970.
7. Ghanem H, Sherif T, Adbel-Gawad T, Asaad T. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction. Int J Impot Res 1998; 10: 211-4.
8. Brock GB. Tadalafil: A new agent for erectile dysfunction. Can J Urol 2003; 10 (suppl 1): 17-22.
9. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP 3rd, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19: 95-103.
10. Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res 2004; 16: 452-5.
11. Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: Results of a large-scale survey. J Sex Med 2004; 1: 284-91.
12. Martín-Morales A. How to promote awareness on sexual health in the general population. J Sex Med 2004; 1: S1; L23: 25-8.
13. Ghanem H, El Sakka A. Sex and sexual dysfunctions in the Middle Eastern culture. In: Tepper MS, Owens AF, eds. Sexual health [four volumes](Sex, love, and psychology). Vol. 3. Westport, CT: Praeger Publications; 2007: 279-96.
14. Goldstein I, Kim E, Steers WD, Pryor JL, Wilde DW, Natanegara F, Wong DG, Ahuja S. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: Results from MOMENTUS: Multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4: 166-75. Erratum in J Sex Med 2007;4:522.
15. Tolra JR, Campana JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 5: 901-9.
16. Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. J Sex Med 2006; 3: 668-75.
17. Morgentaler A, Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, Wong DG. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. J Sex Med 2006; 3: 492-503.
18. The Process of Care Consensus Panel. Position paper: The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11: 59-74.